{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:56:56Z","timestamp":1761101816679},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1007\/s11882-006-0023-6","type":"journal-article","created":{"date-parts":[[2007,6,3]],"date-time":"2007-06-03T00:27:45Z","timestamp":1180830465000},"page":"468-474","source":"Crossref","is-referenced-by-count":4,"title":["Immunodeficiency in childhood"],"prefix":"10.1007","volume":"6","author":[{"given":"Michelle","family":"Hernandez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Bastian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"23_CR1","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.jaci.2005.12.1347","volume":"117","author":"L Notarangelo","year":"2006","unstructured":"Notarangelo L, Casanova JL, Conley ME, et al.: Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee Meeting in Budapest, 2005. J Allergy Clin Immunol 2006, 117:883\u2013896.","journal-title":"J Allergy Clin Immunol"},{"key":"23_CR2","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/S0140-6736(68)92673-1","volume":"28","author":"RA Gatti","year":"1968","unstructured":"Gatti RA, Meuwissen HJ, Allen HD, et al.: Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968, 28:1366\u20131369.","journal-title":"Lancet"},{"key":"23_CR3","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.autrev.2005.10.002","volume":"5","author":"AK Knight","year":"2006","unstructured":"Knight AK, Cunningham-Rundles C: Inflammatory and autoimmune complications of common variable immune deficiency. Autoimmunol Rev 2006, 5:156\u2013159.","journal-title":"Autoimmunol Rev"},{"key":"23_CR4","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.4049\/jimmunol.164.8.4408","volume":"164","author":"I Vorechovsky","year":"2000","unstructured":"Vorechovsky I, Cullen M, Carrington M, et al.: Fine mapping of IGAD1 in IgA deficiency and common variable immunodeficiency: identification and characterization of haplotypes shared by affected members of 101 multiple-case families. J Immunol 2000, 164:4408\u20134416.","journal-title":"J Immunol"},{"key":"23_CR5","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/00130832-200312000-00001","volume":"3","author":"B Grimbacher","year":"2003","unstructured":"Grimbacher B, Warnatz K, Peter HH: The immunological synapse for B-cell memory: the role of the ICOS and its ligand for the longevity of humoral immunity. Curr Opin Allergy Clin Immunol 2003, 3:409\u2013419.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"23_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/16717","volume":"397","author":"A Hutloff","year":"1999","unstructured":"Hutloff A, Dittrich AM, Beier KC, et al.: ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999, 397:263\u2013266.","journal-title":"Nature"},{"key":"23_CR7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/ni902","volume":"4","author":"B Grimbacher","year":"2003","unstructured":"Grimbacher B, Hutloff A, Schlesier M, et al.: Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nat Immunol 2003, 4:261\u2013268.","journal-title":"Nat Immunol"},{"key":"23_CR8","doi-asserted-by":"publisher","first-page":"35478","DOI":"10.1074\/jbc.M005224200","volume":"275","author":"Y Wu","year":"2000","unstructured":"Wu Y, Bressette D, Carrell JA, et al.: Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J Biol Chem 2000, 275:35478\u201335485.","journal-title":"J Biol Chem"},{"key":"23_CR9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S1074-7613(03)00025-6","volume":"18","author":"D Seshasayee","year":"2003","unstructured":"Seshasayee D, Valdez P, Yan M, et al.: Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 2003, 18:279\u2013288.","journal-title":"Immunity"},{"key":"23_CR10","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/ng1601","volume":"37","author":"E Castigli","year":"2005","unstructured":"Castigli E, Wilson SA, Garibyan L, et al.: TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 2005, 37:829\u2013834. This paper and Salzer et al. [11] identified TACI as a significant molecule in human B-cell biology. Its absence accounts for 5% to 10% of CVID cases.","journal-title":"Nat Genet"},{"key":"23_CR11","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/ng1600","volume":"37","author":"U Salzer","year":"2005","unstructured":"Salzer U, Chapel HM, Webster AD, et al.: Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 2005 37:820\u2013828.","journal-title":"Nat Genet"},{"key":"23_CR12","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1056\/NEJMoa051568","volume":"354","author":"MC van Zelm","year":"2006","unstructured":"van Zelm MC, Reisli I, van der BM, et al.: An antibodyde ficiency syndrome due to mutations in the CD19 gene. N Engl J Med 2006, 354:1901\u20131912.","journal-title":"N Engl J Med"},{"key":"23_CR13","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1073\/pnas.91.3.1099","volume":"91","author":"M Farrington","year":"1994","unstructured":"Farrington M, Grosmaire LS, Nonoyama S, et al.: CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency. Proc Natl Acad Sci U S A 1994 91:1099\u20131103.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"23_CR14","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1046\/j.1365-2249.2000.01244.x","volume":"120","author":"H Kanegane","year":"2000","unstructured":"Kanegane H, Tsukada S, Iwata T, et al.: Detection of Bruton\u2019s tyrosine kinase mutations in hypogammaglobulinaemic males registered as common variable immunodeficiency (CVID) in the Japanese Immunodeficiency Registry. Clin Exp Immunol 2000, 120:512\u2013517.","journal-title":"Clin Exp Immunol"},{"key":"23_CR15","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1182\/blood.V98.5.1321","volume":"98","author":"M Morra","year":"2001","unstructured":"Morra M, Silander O, Calpe S, et al.: Alterations of the X-linked lymphoproliferative disease gene SH2D1A in common variable immunodeficiency syndrome. Blood 2001, 98:1321\u20131325.","journal-title":"Blood"},{"key":"23_CR16","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S0167-5699(97)01086-4","volume":"18","author":"GP Spickett","year":"1997","unstructured":"Spickett GP, Farrant J, North ME, et al.: Common variable immunodeficiency: How many diseases?\n                           Immunol Today 1997, 18:325\u2013328.","journal-title":"Immunol Today"},{"key":"23_CR17","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S0022-3476(82)80573-8","volume":"100","author":"BR Powell","year":"1982","unstructured":"Powell BR, Buist NR, Stenzel P: An X-linked syndrome of diarrhea, polyendocrinopathy, and fatal infection in infancy. J Pediatr 1982, 100:731\u2013737.","journal-title":"J Pediatr"},{"key":"23_CR18","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.jaci.2005.08.047","volume":"116","author":"TA Chatila","year":"2005","unstructured":"Chatila TA: Role of regulatory T cells in human diseases. J Allergy Clin Immunol 2005, 116:949\u2013959.","journal-title":"J Allergy Clin Immunol"},{"key":"23_CR19","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1056\/NEJM200106073442304","volume":"344","author":"O Baud","year":"2001","unstructured":"Baud O, Goulet O, Canioni D, et al.: Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation. N Engl J Med 2001, 344:1758\u20131762.","journal-title":"N Engl J Med"},{"key":"23_CR20","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.jaci.2005.08.046","volume":"116","author":"W Lin","year":"2005","unstructured":"Lin W, Truong N, Grossman WJ, et al.: Allergic dysregulation and hyperimmunoglobulinemia E in Foxp3 mutant mice. J Allergy Clin Immunol 2005, 116:1106\u20131115.","journal-title":"J Allergy Clin Immunol"},{"key":"23_CR21","doi-asserted-by":"publisher","first-page":"R75","DOI":"10.1172\/JCI11679","volume":"106","author":"TA Chatila","year":"2000","unstructured":"Chatila TA, Blaeser F, Ho N, et al.: JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest 2000, 106:R75-R81.","journal-title":"J Clin Invest"},{"key":"23_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/83784","volume":"27","author":"ME Brunkow","year":"2001","unstructured":"Brunkow ME, Jeffery EW, Hjerrild KA, et al.: Disruption of a new forkhead\/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001, 27:68\u201373.","journal-title":"Nat Genet"},{"key":"23_CR23","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ni904","volume":"4","author":"JD Fontenot","year":"2003","unstructured":"Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330\u2013336.","journal-title":"Nat Immunol"},{"key":"23_CR24","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1126\/science.1079490","volume":"299","author":"S Hori","year":"2003","unstructured":"Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057\u20131061.","journal-title":"Science"},{"key":"23_CR25","doi-asserted-by":"publisher","first-page":"5138","DOI":"10.1073\/pnas.0501675102","volume":"102","author":"E Bettelli","year":"2005","unstructured":"Bettelli E, Dastrange M, Oukka M: Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Proc Natl Acad Sci U S A 2005, 102:5138\u20135143.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"23_CR26","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s002510100358","volume":"53","author":"CL Bennett","year":"2001","unstructured":"Bennett CL, Brunkow ME, Ramsdell F, et al.: A rare polyadenylation signal mutation of the FOXP3 gene (AAUAAA-->AAUGAA) leads to the IPEX syndrome. Immunogenetics 2001, 53:435\u2013439.","journal-title":"Immunogenetics"},{"key":"23_CR27","doi-asserted-by":"publisher","first-page":"6034","DOI":"10.1210\/jc.2003-031080","volume":"88","author":"CJ Owen","year":"2003","unstructured":"Owen CJ, Jennings CE, Imrie H, et al.: Mutational analysis of the FOXP3 gene and evidence for genetic heterogeneity in the immunodysregulation, polyendocrinopathy, enteropathy syndrome. J Clin Endocrinol Metab 2003, 88:6034\u20136039.","journal-title":"J Clin Endocrinol Metab"},{"key":"23_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.0105-2896.2005.00235.x","volume":"203","author":"CL Ku","year":"2005","unstructured":"Ku CL, Yang K, Bustamante J, et al.: Inherited disorders of human Toll-like receptor signaling: immunological implications. Immunol Rev 2005, 203:10\u201320.","journal-title":"Immunol Rev"},{"key":"23_CR29","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1172\/JCI200318714","volume":"112","author":"G Courtois","year":"2003","unstructured":"Courtois G, Smahi A, Reichenbach J, et al.: A hypermorphic IkappaBalpha mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. J Clin Invest 2003, 112:1108\u20131115.","journal-title":"J Clin Invest"},{"key":"23_CR30","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1126\/science.1081902","volume":"299","author":"C Picard","year":"2003","unstructured":"Picard C, Puel A, Bonnet M, et al.: Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 2003, 299:2076\u20132079.","journal-title":"Science"},{"key":"23_CR31","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1179\/096805105X37367","volume":"11","author":"A Puel","year":"2005","unstructured":"Puel A, Yang K, Ku CL, et al.: Heritable defects of the human TLR signalling pathways. J Endotoxin Res 2005, 11:220\u20132204.","journal-title":"J Endotoxin Res"},{"key":"23_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.coi.2003.11.013","volume":"16","author":"A Puel","year":"2004","unstructured":"Puel A, Picard C, Ku CL, et al.: Inherited disorders of NFkappaB-mediated immunity in man. Curr Opin Immunol 2004, 16:34\u201341.","journal-title":"Curr Opin Immunol"},{"key":"23_CR33","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.immuni.2005.09.016","volume":"23","author":"K Yang","year":"2005","unstructured":"Yang K, Puel A, Zhang S, et al.: Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha\/beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses. Immunity 2005, 23:465\u2013478.","journal-title":"Immunity"},{"key":"23_CR34","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1542\/peds.9.6.722","volume":"9","author":"OC Bruton","year":"1952","unstructured":"Bruton OC: Agammaglobulinemia. Pediatrics 1952, 9:722\u2013728.","journal-title":"Pediatrics"},{"key":"23_CR35","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/0140-6736(91)90147-H","volume":"338","author":"A Gardulf","year":"1991","unstructured":"Gardulf A, Hammarstrom L, Smith CI: Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 1991, 338:162\u2013166.","journal-title":"Lancet"},{"key":"23_CR36","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0140-6736(95)90346-1","volume":"345","author":"A Gardulf","year":"1995","unstructured":"Gardulf A, Andersen V, Bjorkander J, et al.: Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995, 345:365\u2013369.","journal-title":"Lancet"},{"key":"23_CR37","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s10875-006-9021-7","volume":"26","author":"HD Ochs","year":"2006","unstructured":"Ochs HD, Gupta S, Kiessling P, et al.: Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006, 26:265\u2013273. This paper and the next demonstrate the efficacy of a commercial immunoglobulin preparation designed specifically for subcutaneous administration.","journal-title":"J Clin Immunol"},{"key":"23_CR38","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1023\/A:1006678312925","volume":"20","author":"HM Chapel","year":"2000","unstructured":"Chapel HM, Spickett GP, Ericson D, et al.: The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000, 20:94\u2013100.","journal-title":"J Clin Immunol"},{"key":"23_CR39","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10875-006-9002-x","volume":"26","author":"A Gardulf","year":"2006","unstructured":"Gardulf A, Nicolay U, Asensio O, et al.: Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies\u2014a prospective, multi-national study. J Clin Immunol 2006, 26:177\u2013185.","journal-title":"J Clin Immunol"},{"key":"23_CR40","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s10875-006-9031-5","volume":"26","author":"JM Kittner","year":"2006","unstructured":"Kittner JM, Grimbacher B, Wulff W, et al.: Patients\u2019 attitude to subcutaneous immunoglobulin substitution as home therapy. J Clin Immunol 2006, 26:400\u2013405.","journal-title":"J Clin Immunol"},{"key":"23_CR41","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10875-006-8905-x","volume":"26","author":"U Nicolay","year":"2006","unstructured":"Nicolay U, Kiessling P, Berger M, et al.: Health-related quality of life and treatment satisfaction in North American patients with primary immunodeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 2006, 26:65\u201372.","journal-title":"J Clin Immunol"},{"key":"23_CR42","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJM198703053161005","volume":"316","author":"MS Hershfield","year":"1987","unstructured":"Hershfield MS, Buckley RH, Greenberg ML, et al.: Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med 1987, 316:589\u2013596.","journal-title":"N Engl J Med"},{"key":"23_CR43","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJMoa012616","volume":"346","author":"S Hacein-Bey-Abina","year":"2002","unstructured":"Hacein-Bey-Abina S, le Deist F, Carlier F, et al.: Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002, 346:1185\u20131193. This paper documents the first curative human gene therapy.","journal-title":"N Engl J Med"},{"key":"23_CR44","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1126\/science.1088547","volume":"302","author":"S Hacein-Bey-Abina","year":"2003","unstructured":"Hacein-Bey-Abina S, Von KC, Schmidt M, et al.: LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302:415\u2013419.","journal-title":"Science"},{"key":"23_CR45","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/4401123a","volume":"440","author":"NB Woods","year":"2006","unstructured":"Woods NB, Bottero V, Schmidt M, et al.: Gene therapy: therapeutic gene causing lymphoma. Nature 2006, 440:1123.","journal-title":"Nature"},{"key":"23_CR46","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1126\/science.1070104","volume":"296","author":"A Aiuti","year":"2002","unstructured":"Aiuti A, Slavin S, Aker M, et al.: Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002, 296:2410\u20132413. In this experiment, the authors stopped ADA enzyme replacement, which gave a selective advantage to the transfected HSCs and allowed immune reconstitution.","journal-title":"Science"},{"key":"23_CR47","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nm1393","volume":"12","author":"MG Ott","year":"2006","unstructured":"Ott MG, Schmidt M, Schwarzwaelder K, et al.: Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006, 12:401\u2013409.","journal-title":"Nat Med"},{"key":"23_CR48","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/sj.gt.3302570","volume":"12","author":"PL Sinn","year":"2005","unstructured":"Sinn PL, Sauter SL, McCray PB Jr: Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors\u2014design, biosafety, and production. Gene Ther 2005, 12:1089\u20131098.","journal-title":"Gene Ther"},{"key":"23_CR49","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1172\/JCI23966","volume":"115","author":"O Adjali","year":"2005","unstructured":"Adjali O, Marodon G, Steinberg M, et al.: In vivo correction of ZAP-70 immunodeficiency by intrathymic gene transfer. J Clin Invest 2005, 115:2287\u20132295.","journal-title":"J Clin Invest"},{"key":"23_CR50","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/nature03556","volume":"435","author":"FD Urnov","year":"2005","unstructured":"Urnov FD, Miller JC, Lee YL, et al.: Highly efficient endogenous human gene correction using designed zincfinger nucleases. Nature 2005, 435:646\u2013651. This paper describes a method for direct repair of a defective gene that avoids the problems associated with gene insertions.","journal-title":"Nature"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-006-0023-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11882-006-0023-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-006-0023-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-006-0023-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T11:43:40Z","timestamp":1652615020000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11882-006-0023-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["23"],"URL":"https:\/\/doi.org\/10.1007\/s11882-006-0023-6","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"value":"1529-7322","type":"print"},{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}